EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer

Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against NSCLC without EGFR mutations, requiring the identificat...

Descripción completa

Detalles Bibliográficos
Autores principales: Baty, Florent, Rothschild, Sacha, Früh, Martin, Betticher, Daniel, Dröge, Cornelia, Cathomas, Richard, Rauch, Daniel, Gautschi, Oliver, Bubendorf, Lukas, Crowe, Susanne, Zappa, Francesco, Pless, Miklos, Brutsche, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769372/
https://www.ncbi.nlm.nih.gov/pubmed/24039832
http://dx.doi.org/10.1371/journal.pone.0072966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769372/
https://www.ncbi.nlm.nih.gov/pubmed/24039832
http://dx.doi.org/10.1371/journal.pone.0072966

Ejemplares similares